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Abstract. The effect of a treatment versus controls may be expressed in
relative or absolute terms. For rational decision-making, absolute mea-
sures are more meaningful. The number needed to treat, the reciprocal of
the absolute risk reduction, is a powerful estimate of the effect of a
treatment. It is particularly useful because it takes into account the
underlying risk (what would happen without the intervention?). The
number needed to treat tells us not only whether a treatment works but
how well it works. Thus, it informs health care professionals about the
effort needed to achieve a particular outcome. A number needed to treat
should be accompanied by information about the experimental inter-
vention, the control intervention against which the experimental inter-
vention has been tested, the length of the observation period, the
underlying risk of the study population, and an exact definition of the
endpoint. A 95% confidence interval around the point estimate should be
calculated. An isolated number needed to treat is rarely appropriate to
summarize the usefulness of an intervention; multiple numbers needed to
treat for benefit and harm are more helpful. Absolute risk reduction and
number needed to treat should become standard summary estimates in
randomized controlled trials.
The effect of an experimental intervention versus that of a control
intervention may be expressed in relative or absolute terms.
Relative measures are relative risk, relative risk reduction, and
the odds ratio. Absolute measures are absolute risk reduction and
number needed to treat. This article concentrates on the number
needed to treat (or harm).
Relative and Absolute Estimates of Efficacy and Harm
In randomized studies patients are randomly allocated to an
experimental intervention (that is thought to have some beneficial
effects) and to a control intervention. In a placebo-controlled
trial, the control intervention is a placebo; in an active-controlled
trial, the control intervention is another active treatment. The
incidence of an event occurring with the experimental interven-
tion may be called the experimental event rate (EER); accord-
ingly, the incidence of the event occurring with the control
intervention is the control event rate (CER).
Beneficial or harmful effects of the experimental intervention
are usually measured by comparing the probabilities of events in
the experimental and control group, for instance, using the rela-
tive risk (RR) which is the ratio of experimental and control event
rates (RR = EER/CER). Another, related measure is the rela-
tive risk reduction (RRR), which is derived by subtracting the
relative risk from 1 (RRR = 1 ) RR) or by dividing the absolute
difference between the control and experimental event rates by
the control event rate (RRR = [CER ) EER]/CER). The odds
ratio is not discussed here because it is less helpful in clinical
decision-making [1].
There is a main disadvantage, though, of using relative mea-
sures of treatment effects in clinical decision-making, as relative
measures do not reflect the magnitude of the risk without therapy
[2]. The risk without therapy, also called baseline risk or under-
lying risk, may have a major impact on the effect of a treatment.
For instance, when the underlying risk is extremely low, even an
effective therapy has no scope to show efficacy; and when the
underlying risk is extremely high, the efficacy of an intervention
may be exaggerated. Therefore to take into account the under-
lying risk in a study population, the absolute risk reduction
(ARR) is often considered an additional measure of clinical
effectiveness. The absolute risk reduction is the numerical dif-
ference between the control and experimental event rates
(ARR = CER)EER). This number provides an idea about the
clinical relevance of the effect of a treatment. However, even the
absolute risk reduction is problematic as a measure of efficacy or
harm, as it is a dimensionless, abstract number that may be dif-
ficult to incorporate into clinical practice [3]. The number needed
to treat (NNT), which is simply the reciprocal of the absolute risk
reduction (NNT = 1/ARR = 1/[CER)EER]), has the advanta-
ges of the absolute risk reduction and additionally provides a way
of expressing the effect of a treatment in clinical terms. The
number needed to treat is the number of patients who must be
treated with an experimental intervention to achieve a particular
result (beneficial or harmful) in one of them which would not
have been the case had they all received the control intervention
[4]. Table 1 summarizes the relations between experimental and
control event rates, relative risk, relative risk reduction, absolute
risk reduction, and number needed to treat. In analogy to the
quantification of benefit (number needed to treat) and harm
(number needed to harm), the number needed to screen has been
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proposed as a further use of the number needed to treat concept
[5]; this is the number of patients who must be screened for a
disease to prevent one adverse outcome.
It becomes obvious from Table 1 that across different control
event rates, an intervention may have a constant degree of efficacy
in relative terms; however, in absolute terms it makes a huge
difference if the intervention decreases the event rate from 0.5 to
0.2 or from 0.005 to 0.002. In the first case, about three patients
need to be treated for one to show the desired result; in the latter
case, more than 300 patients need to receive the treatment for
one to benefit. Consequently, a number needed to treat must be
interpreted in relation with a control event rate, or, in the ideal
situation, with the true baseline or underlying risk of a study
population or of an individual patient. However, the true
underlying risk is rarely known. In placebo-controlled trials, we
may assume that the incidence of events in the untreated control
group (i.e., the control event rate) reflects to some extent the
underlying risk. Sometimes indicators of the underlying risk are
known; then a close relation between control event rates that are
reported in individual trials and underlying risks in the study
populations may be identified [6].
Specific terms have been used to summarize beneficial or
harmful effects of interventions. For instance, to summarize
beneficial effects, relative beneﬁt, relative and absolute risk
reduction (or decrease), and number needed to treat may be
chosen. For harm, the corresponding terminology is then relative
risk, relative and absolute risk increase, and number needed to
harm. Number needed to treat to beneﬁt and number needed to
treat to harm have also been suggested [7].
It has been shown repeatedly that the way research results are
presented may have an impact on decision-making by health care
professionals. For instance, when trial results were presented as
numbers needed to treat rather than as relative risk reductions,
clinicians rated treatments less effective [8], and they showed less
willingness to prescribe a treatment [9]. Health policymakers were
also shown to be more impressed by measurements that reported
relative benefits compared with those that were based on an index
of absolute benefit [10].
Confidence Interval of the Number Needed to Treat
As with other estimates, the uncertainty in the estimated number
needed to treat is accompanied by a confidence interval [7]. If the
upper limit of the 95% confidence interval (CI) around the
number needed to treat (which puts the intervention in the least
favorable light) still lies within what we would regard as a clini-
cally relevant effect, the intervention is definitely useful. A 95%
CI for the number needed to treat can be constructed by simply
inverting and exchanging the limits of a 95% CI for the absolute
risk reduction [1]. Problems arise, however, when the difference
between experimental and control intervention is not statistically
significant. Then, the 95% CI around the absolute risk reduction
spans from a positive to a negative number and includes 0%. This
result is compatible with three conclusions: First, the experi-
mental intervention is more efficacious than the control inter-
vention (i.e., there is a reduction in the risk of a bad outcome).
Second, there is equivalence, and thus the absolute risk reduction
is 0%. An absolute risk reduction of 0%, however, translates into a
number needed to treat of infinity [7]. Third, the experimental
intervention is less efficacious than the control intervention (i.e.,
there is a ‘‘negative reduction’’ or, accordingly, an increase in the
risk of a bad outcome). This curious situation is illustrated in
Figure 1.
In Figure 1, treatment ‘‘A’’ is significantly more efficacious
than the control treatment. The 95% CI of both the absolute risk
reduction and the corresponding number needed to treat includes
positive numbers only; the values for the number needed to treat,
for instance, expand from +2.5 to +10.0. This result is compatible
with fewer than 3 patients to no more than 10 patients who need
to be treated for one to show a beneficial outcome with treatment
‘‘A’’ compared with the control. For treatment ‘‘B,’’ both the
point estimate and the entire 95% CI are on the negative side of
the axis of the absolute risk reduction. Accordingly, the 95% CI of
the number needed to treat expands from )5 to )2. That result is
compatible with a negative reduction in risk, which may be
interpreted as harm in certain circumstances (see below). Treat-
ment ‘‘C,’’ finally, is not significantly different from the control;
the 95% CI of the absolute risk reduction expands from +20% to
)10% including 0%. The corresponding 95% CI of the number
needed to treat goes from +5 to infinity to )10. Altman suggested
that such a confidence interval should be interpreted as a con-
tinuum that ranges from benefit (i.e., positive absolute risk
reduction and number needed to treat) to equality (i.e., absolute
Table 1. Relation between risk (of efficacy or harm) with treatment and control, relative risk, relative and absolute risk reduction, and number needed
to treat. An alternative way to calculate the relative risk reduction is 1 ) RR.
Risk with treatment Risk with control
EER CER Relative risk Relative risk reduction Absolute risk reduction Number needed to treat
0.2 0.5 0.4 0.6 0.3 3.3
0.02 0.05 0.4 0.6 0.03 33.0
0.002 0.005 0.4 0.6 0.003 333.0
EER: experimental event rate; CER: control event rate; RR: relative risk; RRR: relative risk reduction; ARR: absolute risk reduction.
Fig. 1. Confidence interval for absolute risk reduction and number
needed to treat. Horizontal bars are 95% confidence intervals (Adapted
from Altman [7]).
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risk reduction = 0 and number needed to treat = ¥) to harm
(i.e., negative absolute risk reduction and number needed to treat
or, accordingly, positive absolute risk increase and number nee-
ded to harm) [7]. McQuay and Moore proposed that in such cases
the point estimate of the number needed to treat only should be
reported [3]. As we will see, both interpretations are correct for
specific circumstances.
Interpreting and Using Numbers Needed to Treat
A number needed to treat should always be interpreted in its
proper clinical context. Information should be given about the
experimental intervention (e.g., for drugs: dose, regimen, and
route of administration) and about the control intervention
against which the experimental intervention has been tested
(placebo, no treatment, another active intervention). The length
of the observation period should be defined; models to estimate
numbers needed to treat based on survival data have been pro-
posed [11]. An estimate of the underlying risk of the study pop-
ulation should be provided. Finally, the endpoint should be
specified.
A highly effective intervention has a small number needed to
treat, indicating that only a few subjects need to receive that
intervention for one to profit. However, numbers needed to treat
of less than five are rare in clinical practice. For instance, in
patients at high risk for postoperative vomiting, the most effective
single-dose regimens of antiemetic drugs have numbers needed to
treat of about five to prevent vomiting within 24 hours after
surgery compared with placebo [12]. In patients having moderate
to severe pain after minor surgical procedures (e.g., wisdom tooth
removal), an adequate single oral dose of an nonsteroidal ant-
itinflammatory drug has a number needed to treat of two to three
compared with placebo for at least 50% pain relief during a 6-
hour period [13]. Obviously, the clinical relevance of the effect of
an intervention depends not only on the numerical value of the
number needed to treat but also on the severity of the outcome.
For instance, when inserted for no more than 1 week, antibiotic-
coated central venous catheters have a number needed to treat to
prevent bloodstream infection of about 20 compared with un-
treated catheters [14]. This relatively high number needed to treat
is likely to be of clinical relevance because, unlike postoperative
vomiting or pain, bloodstream infection is potentially lethal.
Examples of summary estimates of efficacy and harm from
randomized controlled trials from perioperative medicine are
shown in Table 2 and and Figure 2 [15–21]. Smoking cessation
before surgery [15], endovascular coiling of intracranial aneu-
rysms [16], and perioperative b-blockade [17] are clearly associ-
ated with beneficial outcomes: numbers needed to treat for one
successful outcome compared with the respective comparators
range from 4 to 14, and all 95% CIs include positive numbers
only.
The already mentioned impact of the underlying risk on the
efficacy of an intervention is well illustrated by the study on
perioperative b-blockade (Figure 2) [17]. This study suggested
that about eight patients undergoing noncardiac surgery need to
receive perioperative bisoprolol to prevent one cardiac death. In
that trial, however, 50% of the randomized patients had a history
of previous myocardial infarction, one-third had angina pectoris,
one-third had limited exercise capacity, and 15% had diabetes
mellitus. Of the patients in the control group who did not receive
b-blockade, 17% died within 30 days owing to cardiac causes. This
unusually high control event rate places in question the applica-
bility of the trial. The study population may not necessarily rep-
resent what most anesthesiologists and surgeons see in daily
clinical practice. It is likely that only the selection of patients with
an extremely high underlying risk made it possible to demonstrate
such an extraordinary benefit with b-blockade. Indeed, in similar
randomized trials that included populations with much lower
underlying risks (and thus lower control even rates), the beneficial
effect of perioperative b-blockade was less pronounced [22].
The fourth example in Figure 2 is about patients with sepsis
who received 6% hydroxyethylstarch or 6% gelatin solution [18].
With hydroxyethylstarch there was a significantly higher rate of
acute renal failure; the absolute reduction in the risk of renal
failure was )18% (95% CI )2% to )34%), and the corresponding
numbers needed to treat was )5.5 (95% .CI )44.0 to )2.9). This
result may be interpreted as an absolute increase in the risk of
having renal failure with hydroxyethylstarch of 18% (95%, CI
+2% to +34%) and a corresponding number needed to harm of
5.5 (95% CI +2.9 to +44.0).
The three last examples in Figure 2—epidural anesthesia [19],
restricted transfusion strategy [20], and pulmonary artery cathe-
ter-guided therapy [21]—report on results that are not statistically
significant; the 95% CI around the absolute risk reduction in-
cludes 0%, and around the number needed to treat it includes
infinity. These interventions are not significantly different from
their active controls. The methodologically correct interpretation
of the 95% CI around the estimate of efficacy is a continuum that
ranges from benefit to equality to harm [7]. Thus the data of all
three trials are compatible with the experimental intervention
having a beneficial effect compared with the control intervention,
or with equivalence, or with the experimental intervention actu-
ally increasing the risk of a bad outcome compared with the
control intervention. In clinical practice, we would simply con-
clude that there is no evidence of any difference between the
experimental and control interventions.
A limitation of this technically correct interpretation of the 95%
CI interval around the number needed to treat when the com-
parison is not statistically significant is shown in Figure 3. The
figure summarizes the dose-response of the antiemetic efficacy of
droperidol when added to morphine in a patient-controlled
analgesia device [23]. With the lowest regimen tested, 5 lg of
droperidol added to 1 mg of morphine, the number needed to
treat is 16, and the 95% CI ranges from +4.7 to )11.0; indicating
that this dose is not statistically significantly different from pla-
cebo. Uncritical application of the rules that were discussed
earlier (Table 2, Fig. 2) would lead to the conclusion that the
upper limit of the confidence interval corresponds to a number
needed to harm of +11, and therefore the antiemetic droperidol
had the potential to cause emesis. This, obviously, does not make
sense from a pharmacologic point of view. Therefore, for com-
parisons between an experimental intervention and a placebo
control that do not show a statistically significant difference it may
indeed be useful to provide the point estimate of the number
needed to treat only and to ignore the 95% CI [3].
For a rational use of the number needed to treat, two further
issues must be addressed. First, it is rarely adequate to summarize
the usefulness of an intervention with a single number needed to
treat. For instance, there is no benefit in survival in critically ill
patients with Swan-Ganz catheter-guided therapy compared with
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standard therapy (Table 2, Fig. 2) [21]. However, 8 of 997 (0.8%)
patients who had a pulmonary catheter had a pulmonary embo-
lism, and none of 997 controls had such a complication; this dif-
ference was statistically significant, the number needed to harm
was 125 (95% CI 74–402). The combination of lack of efficacy and
presence of major harm challenges even more the usefulness of
pulmonary catheters. Reporting on multiple numbers needed to
treat, for both beneficial and harmful outcomes, provides the
most powerful tool for rational decision-making about the use-
fulness of medical interventions.
Second, to implement data from well designed clinical studies
into clinical practice implies bringing summary estimates down to
an individual patient level, which is a particular challenge [24].
Models that take into account estimates of efficacy and harm from
randomized controlled trials and knowledge from observational
studies on factors that predict the underlying risk have been
proposed [25].
Conclusions
The effect of a treatment over a control may be expressed in
relative or absolute terms. Both ways have advantages and dis-
advantages; however, for rational decision-making in daily clinical
practice, absolute measures are more meaningful. The number
needed to treat (and harm) is a powerful estimate of the effect of
a treatment. It is particularly useful because it takes into account
the underlying risk (what would happen without the interven-
tion?). The number needed to treat not only tells us whether a
treatment works but also how well it works. This number informs
health care professionals about the effort that is needed to
achieve a particular outcome. Some simple rules must be con-
sidered, though, to avoid misuse of the number needed to treat.
For instance, the number needed to treat should be correctly
reported, and information about the clinical context should be
provided. Also, a single number needed to treat is rarely appro-
priate for summarizing the usefulness of an intervention; multiple
numbers needed to treat for distinct beneficial and harmful out-
comes should be provided. Hopefully, the number needed to treat
will become a standard summary estimate in randomized con-
trolled trials [26].
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